FDA approved AMVUTTRA® (vutrisiran), the first RNAi therapeutic to reduce cardiovascular death, hospitalizations and urgent heart failure visits in adults with ATTR-CM
PUBLICATION_TIME(BEIJING): 2025-03-21 5:54:00
PROVIDER: Alnylam Pharmaceuticals, Inc.
HEADLINE: Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits